{"id":"chewing-ticagrelor-ld","safety":{"commonSideEffects":[{"rate":"4-6","effect":"Bleeding"},{"rate":"3-5","effect":"Bradycardia"},{"rate":"2-4","effect":"Dyspnea"},{"rate":"1-2","effect":"Ventricular pauses"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ticagrelor binds directly and reversibly to the P2Y12 adenosine diphosphate (ADP) receptor on platelets, blocking platelet activation and aggregation. This antiplatelet effect reduces the formation of blood clots and is used to prevent cardiovascular events in acute coronary syndromes and other thrombotic conditions. The chewing formulation (low-dose loading dose) allows for rapid onset of action in acute settings.","oneSentence":"Ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation and reduces thrombotic events.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:20.712Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) for prevention of thrombotic cardiovascular events"},{"name":"Secondary prevention of atherothrombotic events in patients with acute myocardial infarction"}]},"trialDetails":[{"nctId":"NCT03016611","phase":"PHASE4","title":"Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2017-02","conditions":"Acute Coronary Syndrome, STEMI","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Chewing Ticagrelor LD","genericName":"Chewing Ticagrelor LD","companyName":"Sheba Medical Center","companyId":"sheba-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation and reduces thrombotic events. Used for Acute coronary syndrome (ACS) for prevention of thrombotic cardiovascular events, Secondary prevention of atherothrombotic events in patients with acute myocardial infarction.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}